Compare · APLT vs TVTX
APLT vs TVTX
Side-by-side comparison of Applied Therapeutics Inc. (APLT) and Travere Therapeutics Inc. (TVTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both APLT and TVTX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- TVTX is the larger of the two at $4.38B, about 61.9x APLT ($70.8M).
- Over the past year, APLT is down 72.7% and TVTX is up 216.1% - TVTX leads by 288.7 points.
- TVTX has hit the wire 15 times in the past 4 weeks while APLT has been quiet.
- TVTX has more recent analyst coverage (25 ratings vs 11 for APLT).
- Company
- Applied Therapeutics Inc.
- Travere Therapeutics Inc.
- Price
- $0.11+5.91%
- $47.08+2.83%
- Market cap
- $70.8M
- $4.38B
- 1M return
- +3.66%
- +10.28%
- 1Y return
- -72.67%
- +216.08%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- News (4w)
- 0
- 15
- Recent ratings
- 11
- 25
Applied Therapeutics Inc.
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase I/II for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.
Travere Therapeutics Inc.
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences, and Alagille Syndrome Alliance for identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Latest APLT
- SEC Form 15-12G filed by Applied Therapeutics Inc.
- SEC Form EFFECT filed by Applied Therapeutics Inc.
- SEC Form EFFECT filed by Applied Therapeutics Inc.
- Director Kanter Stacy J. returned 22,500 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Commercial Officer Hooks Corwin Dale was granted 312,500 shares and returned 862,500 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Officer Chinoporos Constantine was granted 437,500 shares and returned 1,000,000 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Skyler Jay S returned 22,500 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Financial Officer Funtleyder Leslie D. was granted 1,187,500 shares and returned 2,375,000 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Medical Officer Bailey Evan Prescott returned 1,235,915 shares to the company and was granted 437,500 shares, closing all direct ownership in the company (SEC Form 4)
- Director Lerner Teena returned 22,500 shares to the company, closing all direct ownership in the company (SEC Form 4)
Latest TVTX
- Travere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63rd European Renal Association (ERA) 2026 Congress
- SEC Form 8-K filed by Travere Therapeutics Inc.
- Travere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases
- Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in IgA Nephropathy
- Director Williams Brinkley Ruth was granted 4,000 shares, increasing direct ownership by 16% to 29,750 units (SEC Form 4)
- Director Meckler Jeffrey A was granted 4,000 shares, increasing direct ownership by 5% to 91,500 units (SEC Form 4)
- Director Orwin John A was granted 4,000 shares, increasing direct ownership by 11% to 39,375 units (SEC Form 4)
- Director Poole Sandra was granted 4,000 shares, increasing direct ownership by 13% to 34,000 units (SEC Form 4)
- Director Squarer Ron was granted 4,000 shares, increasing direct ownership by 11% to 39,375 units (SEC Form 4)
- Director Baynes Roy D. was granted 4,000 shares, increasing direct ownership by 11% to 41,500 units (SEC Form 4)